Key result
Admission serum endocan was significantly elevated in patients with acute heart failure and cardiogenic shock compared to controls (p < 0.001), and correlated with left ventricular ejection fraction impairment.
Why the study?
Endocan contributes to inflammation and endothelial dysfunction, but has been scarcely explored in human acute heart failure.
Population
23 AHF patients, 25 CS patients, and 22 blood donor controls
Comparison
AHF vs CS vs controls
Design
Prospective cohort study
Authors
Loading...
Endocan elevation was associated with acute HF and shock severity; leaves open its role as an endothelial biomarker pending validation.
Cohort (n=70)
No
p-value: p=<0.001
Serum endocan is significantly elevated in acute heart failure and cardiogenic shock, correlating with disease severity and prognostic scores, suggesting its potential as a biomarker for endothelitis.
Reina‐Couto et al. (2022) conducted a cohort in Acute heart failure and cardiogenic shock (n=70). Acute heart failure and cardiogenic shock vs. Healthy controls was evaluated on Admission serum endocan (S-Endocan) concentration (p=<0.001). Admission serum endocan was significantly elevated in patients with acute heart failure and cardiogenic shock compared to controls (p < 0.001), and correlated with left ventricular ejection fraction impairment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: